Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Type
Public
HQ
Milton, GB
Founded
2003
Size (employees)
44 (est)
Summit Therapeutics was founded in 2003 and is headquartered in Milton, GB
Report incorrect company information

Summit Therapeutics Office Locations

Summit Therapeutics has offices in Milton and Cambridge
Milton, GB (HQ)
Park House Park Dr 85b
Cambridge, US
1 Broadway
Show all (2)
Report incorrect company information

Summit Therapeutics Financials and Metrics

Summit Therapeutics Financials

Summit Therapeutics's revenue was reported to be £2.30 m in FY, 2017
GBP

Revenue (FY, 2017)

2.3 m

Net income (FY, 2017)

(21.4 m)

EBITDA (FY, 2017)

(24.8 m)

EBIT (FY, 2017)

(24.9 m)

Market capitalization (31-Oct-2017)

96 m

Closing share price (31-Oct-2017)

1.6

Cash (31-Jan-2017)

28.1 m
Summit Therapeutics's current market capitalization is £96 m.
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3 m1.8 m189 k763 k1.8 m1.8 m1.8 m2.1 m1.5 m2.3 m

Revenue growth, %

16%(32%)

Cost of goods sold

1.6 m1.1 m

Gross profit

1.4 m773 k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.1 m2.7 m6.1 m3.3 m2.1 m3.4 m2 m11.3 m16.3 m28.1 m

Accounts Receivable

189 k651 k41 k32 k47 k51 k

Inventories

337 k391 k

Current Assets

12.7 m5.4 m6.6 m3.7 m2.6 m4.2 m3.1 m15.2 m20.8 m33.3 m
GBPY, 2017

Revenue/Employee

56.9 k

Financial Leverage

-10.8 x
Show all financial metrics
Report incorrect company information

Summit Therapeutics News and Updates

Report incorrect company information